Relapses of Crohn’s disease, an inflammatory bowel condition, lessened the efficacy of Soliris (eculizumab) in an adolescent girl with atypical hemolytic uremic syndrome (aHUS), a case study reported. “Increased doses of [Soliris] may be necessary to maintain therapeutic blood levels of [Soliris] and full complement blockade, especially if…
Treatment with Soliris (eculizumab) led to successful resolution of atypical hemolytic uremic syndrome (aHUS) that was triggered by inflammatory bowel disease (IBD), a study of two cases has found. The study, “Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel…
Bloody stools in children with atypical hemolytic uremic syndrome (aHUS) may indicate the simultaneous presence of inflammatory bowel disease (IBD), three case studies report. These findings raise questions about the connection between aHUS and its associated defects in the complement system, and the gut inflammation characteristic of…
Get regular updates to your inbox.